The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma: e0126615

The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma: e0126615

The prognostic value of CD30 expression indiffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2015-05, Vol.10 (5)
Hauptverfasser: Hao, Xiaoxiao, Wei, Xiaolei, Huang, Fen, Wei, Yongqiang, Zeng, Hong, Xu, Linwei, Zhou, Qinjun, Feng, Ru
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page
container_title PloS one
container_volume 10
creator Hao, Xiaoxiao
Wei, Xiaolei
Huang, Fen
Wei, Yongqiang
Zeng, Hong
Xu, Linwei
Zhou, Qinjun
Feng, Ru
description The prognostic value of CD30 expression indiffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67overexpression(p
doi_str_mv 10.1371/journal.pone.0126615
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1762362711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1762362711</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_17623627113</originalsourceid><addsrcrecordid>eNqVjk1OwzAQhS0kJMrPDVjMkk2CHasOsGxaRKVKdNF9ZaUT4ir2BI8t6Am4Nln0Al190vvRe0I8KlkqXavnI-UY7FCOFLCUqjJGza_ETL3qqjCV1Dfilvko5Vy_GDMTf7seYfU7RmR2FIA6aJZawsIyHmAS1t7nQL3jRG2PfmI8wTbiwbWJYR06jI4ifObUkkdwAbY2OQyT-eNSD0vXdZkRNjZ-ISyKBocBNic_9uTtG-D54r247uzA-HDmnXh6X-2aj2KM9J2R036abqeuDUiZ96o2lTZVrZS-IPoP_RlcaA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762362711</pqid></control><display><type>article</type><title>The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma: e0126615</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hao, Xiaoxiao ; Wei, Xiaolei ; Huang, Fen ; Wei, Yongqiang ; Zeng, Hong ; Xu, Linwei ; Zhou, Qinjun ; Feng, Ru</creator><creatorcontrib>Hao, Xiaoxiao ; Wei, Xiaolei ; Huang, Fen ; Wei, Yongqiang ; Zeng, Hong ; Xu, Linwei ; Zhou, Qinjun ; Feng, Ru</creatorcontrib><description>The prognostic value of CD30 expression indiffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67overexpression(p&lt;0.05). Patients with CD30 expression showed significantly poor overall and event-free survivalcompared with CD30 negative patients(p = 0.031 and 0.041, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI)(p = 0.001 and 0.007, respectively). The prognostic value of CD30expression retained in DLBCL patients treated with eitherCHOP (cyclophosphamide, doxorubicin, vincristine,prednisone) or R-CHOP(rituximab+CHOP). The multivariate analysisrevealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival (p = 0.001 and 0.002, respectively).In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCBDLBCL. The expression of CD30 implied poor outcomein DLBCL patientstreated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.</description><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0126615</identifier><language>eng</language><ispartof>PloS one, 2015-05, Vol.10 (5)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids></links><search><creatorcontrib>Hao, Xiaoxiao</creatorcontrib><creatorcontrib>Wei, Xiaolei</creatorcontrib><creatorcontrib>Huang, Fen</creatorcontrib><creatorcontrib>Wei, Yongqiang</creatorcontrib><creatorcontrib>Zeng, Hong</creatorcontrib><creatorcontrib>Xu, Linwei</creatorcontrib><creatorcontrib>Zhou, Qinjun</creatorcontrib><creatorcontrib>Feng, Ru</creatorcontrib><title>The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma: e0126615</title><title>PloS one</title><description>The prognostic value of CD30 expression indiffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67overexpression(p&lt;0.05). Patients with CD30 expression showed significantly poor overall and event-free survivalcompared with CD30 negative patients(p = 0.031 and 0.041, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI)(p = 0.001 and 0.007, respectively). The prognostic value of CD30expression retained in DLBCL patients treated with eitherCHOP (cyclophosphamide, doxorubicin, vincristine,prednisone) or R-CHOP(rituximab+CHOP). The multivariate analysisrevealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival (p = 0.001 and 0.002, respectively).In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCBDLBCL. The expression of CD30 implied poor outcomein DLBCL patientstreated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.</description><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqVjk1OwzAQhS0kJMrPDVjMkk2CHasOsGxaRKVKdNF9ZaUT4ir2BI8t6Am4Nln0Al190vvRe0I8KlkqXavnI-UY7FCOFLCUqjJGza_ETL3qqjCV1Dfilvko5Vy_GDMTf7seYfU7RmR2FIA6aJZawsIyHmAS1t7nQL3jRG2PfmI8wTbiwbWJYR06jI4ifObUkkdwAbY2OQyT-eNSD0vXdZkRNjZ-ISyKBocBNic_9uTtG-D54r247uzA-HDmnXh6X-2aj2KM9J2R036abqeuDUiZ96o2lTZVrZS-IPoP_RlcaA</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Hao, Xiaoxiao</creator><creator>Wei, Xiaolei</creator><creator>Huang, Fen</creator><creator>Wei, Yongqiang</creator><creator>Zeng, Hong</creator><creator>Xu, Linwei</creator><creator>Zhou, Qinjun</creator><creator>Feng, Ru</creator><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20150501</creationdate><title>The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma: e0126615</title><author>Hao, Xiaoxiao ; Wei, Xiaolei ; Huang, Fen ; Wei, Yongqiang ; Zeng, Hong ; Xu, Linwei ; Zhou, Qinjun ; Feng, Ru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_17623627113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hao, Xiaoxiao</creatorcontrib><creatorcontrib>Wei, Xiaolei</creatorcontrib><creatorcontrib>Huang, Fen</creatorcontrib><creatorcontrib>Wei, Yongqiang</creatorcontrib><creatorcontrib>Zeng, Hong</creatorcontrib><creatorcontrib>Xu, Linwei</creatorcontrib><creatorcontrib>Zhou, Qinjun</creatorcontrib><creatorcontrib>Feng, Ru</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hao, Xiaoxiao</au><au>Wei, Xiaolei</au><au>Huang, Fen</au><au>Wei, Yongqiang</au><au>Zeng, Hong</au><au>Xu, Linwei</au><au>Zhou, Qinjun</au><au>Feng, Ru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma: e0126615</atitle><jtitle>PloS one</jtitle><date>2015-05-01</date><risdate>2015</risdate><volume>10</volume><issue>5</issue><eissn>1932-6203</eissn><abstract>The prognostic value of CD30 expression indiffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67overexpression(p&lt;0.05). Patients with CD30 expression showed significantly poor overall and event-free survivalcompared with CD30 negative patients(p = 0.031 and 0.041, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI)(p = 0.001 and 0.007, respectively). The prognostic value of CD30expression retained in DLBCL patients treated with eitherCHOP (cyclophosphamide, doxorubicin, vincristine,prednisone) or R-CHOP(rituximab+CHOP). The multivariate analysisrevealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival (p = 0.001 and 0.002, respectively).In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCBDLBCL. The expression of CD30 implied poor outcomein DLBCL patientstreated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.</abstract><doi>10.1371/journal.pone.0126615</doi></addata></record>
fulltext fulltext
identifier EISSN: 1932-6203
ispartof PloS one, 2015-05, Vol.10 (5)
issn 1932-6203
language eng
recordid cdi_proquest_miscellaneous_1762362711
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry
title The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma: e0126615
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A21%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Expression%20of%20CD30%20Based%20on%20Immunohistochemistry%20Predicts%20Inferior%20Outcome%20in%20Patients%20with%20Diffuse%20Large%20B-Cell%20Lymphoma:%20e0126615&rft.jtitle=PloS%20one&rft.au=Hao,%20Xiaoxiao&rft.date=2015-05-01&rft.volume=10&rft.issue=5&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0126615&rft_dat=%3Cproquest%3E1762362711%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1762362711&rft_id=info:pmid/&rfr_iscdi=true